Erin Elizabeth Hahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erin Elizabeth Hahn has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Beverly B. Green
Kaiser Permanente Washington Health Research Institute, Seattle, Washington
17 shared publications - Caitlin C. Murphy
Section of Hematology and Oncology,Department of Pediatrics, The University of Chicago, Chicago, USA
17 shared publications - Celette Sugg Skinner
Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX
17 shared publications - Cynthia Ortiz
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas
17 shared publications - Ellen Hu
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas
17 shared publications - Eric J. Kim
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas
17 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020
Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020
Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Predictive Risk Model for Early Post-Treatment Acute Care Use in Adolescent and Young Adult Patients With Cancer
PURPOSE: Adolescent and young adult (AYA) patients with cancer (ages 15-39 years at diagnosis) continue to have health care needs after completing treatment. Risk models to predict acute care events (ACEs) in this population may lead to earlier identification of high-risk populations. This study aimed to develop and validate a clinical risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. METHODS: Using the University of North Carolina Lineberger Cancer Information and Population Health Resource, we identified AYAs diagnosed between 2006 and 2018 who were 2-5 years after diagnosis. The primary outcome was any ACE, defined as either hospitalization or emergency department (ED) visit. Patients were randomly assigned to development (70%) and validation (30%) cohorts. Logistic regression models were developed using stepwise inclusion of predictive variables. Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), and AUC. RESULTS: The study cohort included 7,393 patients (development = 5,276, validation = 2,217) with an average follow-up of 1.9 years. The most common cancers were breast (17%), thyroid (14%), and gynecologic (10%). Patients with ACEs (n = 3,572, 48%) were more frequently female, Black, and publicly insured. Defining high risk as the top 20% of scores, in the validation cohort, the selected model achieved an AUC of 0.76, a specificity of 0.94, a sensitivity of 0.34, and a PPV of 0.84. CONCLUSION: This is the first validated risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. The model, designed for seamless electronic health record integration, enables early identification of high-risk patients, presenting opportunities for targeted interventions to reduce acute care use. Further validation across different health care systems is planned and will expand clinical applicability.
- 25 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Predictive Risk Model for Early Post-Treatment Acute Care Use in Adolescent and Young Adult Patients With Cancer
PURPOSE: Adolescent and young adult (AYA) patients with cancer (ages 15-39 years at diagnosis) continue to have health care needs after completing treatment. Risk models to predict acute care events (ACEs) in this population may lead to earlier identification of high-risk populations. This study aimed to develop and validate a clinical risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. METHODS: Using the University of North Carolina Lineberger Cancer Information and Population Health Resource, we identified AYAs diagnosed between 2006 and 2018 who were 2-5 years after diagnosis. The primary outcome was any ACE, defined as either hospitalization or emergency department (ED) visit. Patients were randomly assigned to development (70%) and validation (30%) cohorts. Logistic regression models were developed using stepwise inclusion of predictive variables. Model performance was evaluated using sensitivity, specificity, positive predictive value (PPV), and AUC. RESULTS: The study cohort included 7,393 patients (development = 5,276, validation = 2,217) with an average follow-up of 1.9 years. The most common cancers were breast (17%), thyroid (14%), and gynecologic (10%). Patients with ACEs (n = 3,572, 48%) were more frequently female, Black, and publicly insured. Defining high risk as the top 20% of scores, in the validation cohort, the selected model achieved an AUC of 0.76, a specificity of 0.94, a sensitivity of 0.34, and a PPV of 0.84. CONCLUSION: This is the first validated risk model to predict ACEs in AYA patients with cancer during the early post-treatment period. The model, designed for seamless electronic health record integration, enables early identification of high-risk patients, presenting opportunities for targeted interventions to reduce acute care use. Further validation across different health care systems is planned and will expand clinical applicability.
- 6 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , e507-e513
Clinical Decision Support for Service Coverage of AYA Palliative Care: An Interrupted Time Series
- 6 August 2026
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 72 (6) , e507-e513
Clinical Decision Support for Service Coverage of AYA Palliative Care: An Interrupted Time Series
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 780-792
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
PURPOSE: Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS: Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS: Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION: Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 780-792
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
PURPOSE: Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS: Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS: Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION: Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
- Open Access
- 27 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (23) , e71316
Identifying Patterns of Late Effects With Latent Class Analysis Among Adolescent and Young Adult Thyroid Cancer Survivors in California and Utah
Introduction: Thyroid cancer is one of the most common cancers in adolescents and young adults (AYA, 15 to 39 years), with an excellent 5‐year survival of 98%. However, treatments for thyroid cancer such as radioactive iodine and thyroid hormone suppression may increase the risk for multiple late effects (LEs). We investigated the incidence of severe LE that clustered in AYA thyroid cancer survivors in a large population‐based cohort. Methods: California and Utah Cancer Registry records identified AYAs diagnosed with first thyroid cancer during 2006–2018 linked to statewide hospitalization, ambulatory surgery, and emergency department data. Cohort entry began 2 years from diagnosis. Severe LE included cardiovascular, respiratory, renal, and liver diseases, diabetes, and second cancers. Cumulative incidence of each LE, accounting for the competing risk of death, was calculated. Latent class analysis (LCA) identified clustering of LE over the study period. The number of LE classes was identified by selecting models with the lowest likelihood‐ratio G 2 statistic, Akaike's Information Criterion, and Bayesian Information Criterion. Probabilities of each LE are presented in each class. Results: Of 14,268 survivors, median follow‐up time was 7 years. The LCA model identified 3 classes: 88% with low LEs, 9% experiencing moderate LEs with elevated probability of diabetes, liver, and respiratory conditions, and the remaining 3% experiencing the highest probability of all LEs, including cardiovascular disease. Non‐Hispanic (nH)‐Black and Hispanic survivors, those on public insurance, residing in lower socioeconomic status neighborhoods, or diagnosed with distant stage disease experience greater odds of being in the moderate and cardiovascular classes. Conclusion: While most survivors of AYA thyroid cancer have a low incidence of LEs, a small proportion have a high probability of multiple morbidities. Multidisciplinary survivorship care should include identifying and supporting thyroid cancer survivors at higher risk for developing multiple LEs through early screening.
- 27 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (23) , e71316
Open AccessIdentifying Patterns of Late Effects With Latent Class Analysis Among Adolescent and Young Adult Thyroid Cancer Survivors in California and Utah
Introduction: Thyroid cancer is one of the most common cancers in adolescents and young adults (AYA, 15 to 39 years), with an excellent 5‐year survival of 98%. However, treatments for thyroid cancer such as radioactive iodine and thyroid hormone suppression may increase the risk for multiple late effects (LEs). We investigated the incidence of severe LE that clustered in AYA thyroid cancer survivors in a large population‐based cohort. Methods: California and Utah Cancer Registry records identified AYAs diagnosed with first thyroid cancer during 2006–2018 linked to statewide hospitalization, ambulatory surgery, and emergency department data. Cohort entry began 2 years from diagnosis. Severe LE included cardiovascular, respiratory, renal, and liver diseases, diabetes, and second cancers. Cumulative incidence of each LE, accounting for the competing risk of death, was calculated. Latent class analysis (LCA) identified clustering of LE over the study period. The number of LE classes was identified by selecting models with the lowest likelihood‐ratio G 2 statistic, Akaike's Information Criterion, and Bayesian Information Criterion. Probabilities of each LE are presented in each class. Results: Of 14,268 survivors, median follow‐up time was 7 years. The LCA model identified 3 classes: 88% with low LEs, 9% experiencing moderate LEs with elevated probability of diabetes, liver, and respiratory conditions, and the remaining 3% experiencing the highest probability of all LEs, including cardiovascular disease. Non‐Hispanic (nH)‐Black and Hispanic survivors, those on public insurance, residing in lower socioeconomic status neighborhoods, or diagnosed with distant stage disease experience greater odds of being in the moderate and cardiovascular classes. Conclusion: While most survivors of AYA thyroid cancer have a low incidence of LEs, a small proportion have a high probability of multiple morbidities. Multidisciplinary survivorship care should include identifying and supporting thyroid cancer survivors at higher risk for developing multiple LEs through early screening.
Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer
Background: Few studies have assessed the burden of chronic medical conditions in adolescent and young adult (AYA) cancer survivors. This study estimated the risk of these conditions among AYA survivors compared to a matched cohort without cancer. Methods: This retrospective cohort study included 2‐year survivors ( n = 14,917) of 11 common AYA (15–39 years) cancers diagnosed at the integrated health care organizations of Kaiser Permanente (KP) Southern and Northern California during 2006–2020. A comparison cohort ( n = 149,164) without cancer (matched 10:1 by age, sex, calendar year, and KP site) was included. Cumulative incidence (CMI) accounting for death as a competing risk was calculated. Poisson regression estimated the incidence rate ratio (IRR) of each condition in cancer survivors versus the matched cohort, adjusting for age, sex, and race/ethnicity. Results: The 5‐year CMI was highest for thyroid (17.4%), respiratory (6.6%), cardiovascular (5.0%), and liver (4.8%) diseases. At 10 years, the CMI of any condition was 39% in survivors versus 26% in the matched cohort. Survivors had a 2‐fold increased risk of being diagnosed with any medical condition (IRR, 2.0; 95% confidence interval [CI], 1.9–2.0) as well as two or more conditions (IRR, 2.3; 95% CI, 2.2–2.5). Risk was highest among survivors of hematologic cancers and those diagnosed with distant stage disease. Elevated risks were observed within all sociodemographic groups of this insured population. Conclusion: AYAs with cancer had a higher risk of chronic medical conditions compared to those without cancer. Long‐term surveillance, risk mitigation through lifestyle modifications and effective disease management are crucial to reduce premature mortality.
Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer
Background: Few studies have assessed the burden of chronic medical conditions in adolescent and young adult (AYA) cancer survivors. This study estimated the risk of these conditions among AYA survivors compared to a matched cohort without cancer. Methods: This retrospective cohort study included 2‐year survivors ( n = 14,917) of 11 common AYA (15–39 years) cancers diagnosed at the integrated health care organizations of Kaiser Permanente (KP) Southern and Northern California during 2006–2020. A comparison cohort ( n = 149,164) without cancer (matched 10:1 by age, sex, calendar year, and KP site) was included. Cumulative incidence (CMI) accounting for death as a competing risk was calculated. Poisson regression estimated the incidence rate ratio (IRR) of each condition in cancer survivors versus the matched cohort, adjusting for age, sex, and race/ethnicity. Results: The 5‐year CMI was highest for thyroid (17.4%), respiratory (6.6%), cardiovascular (5.0%), and liver (4.8%) diseases. At 10 years, the CMI of any condition was 39% in survivors versus 26% in the matched cohort. Survivors had a 2‐fold increased risk of being diagnosed with any medical condition (IRR, 2.0; 95% confidence interval [CI], 1.9–2.0) as well as two or more conditions (IRR, 2.3; 95% CI, 2.2–2.5). Risk was highest among survivors of hematologic cancers and those diagnosed with distant stage disease. Elevated risks were observed within all sociodemographic groups of this insured population. Conclusion: AYAs with cancer had a higher risk of chronic medical conditions compared to those without cancer. Long‐term surveillance, risk mitigation through lifestyle modifications and effective disease management are crucial to reduce premature mortality.
- Open Access
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (6)
Identifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma
Background: We examined late effects clustering among adolescent and young adult (AYA; age 15-39 years at diagnosis) Hodgkin lymphoma (HL) survivors and identified characteristics associated with each cluster. Methods: We included AYAs with HL in 2006-2018 from the California and Utah Cancer Registries linked to statewide hospitalization, emergency department, and ambulatory surgery visit data. We identified severe late effects >2 years after cancer diagnosis in 9 late effects categories. Latent class analysis (LCA) was used to identify late effects clusters. Multinomial logistic regression models estimated adjusted associations of demographic and treatment characteristics with LCA late effect group. Results: We identified 4635 AYA HL survivors with median follow-up of 8.2 years and 4 late effects groups: 77.1% had a low probability of any late effect (Low Morbidity), 12.8% had high probability of Thyroid disorders, 8.0% had high probability of Cardiovascular Disease (CVD), and 2.1% had high probability of Multiple Conditions (CVD, diabetes/pancreatic, thyroid, and renal diseases). Publicly insured AYAs were more likely than those with private insurance to be in the CVD (OR = 1.53, 95% CI = 1.18 to 1.98) and Multiple Conditions (OR = 2.17, 95% CI = 1.29 to 3.66) than the Low Morbidity group. AYAs with radiation were more likely to be in the Multiple Conditions (OR = 2.31, 95% CI = 1.41 to 3.78) and Thyroid (OR = 2.81, 95% CI = 2.20 to 3.58) groups. Hematopoietic cell transplantation was associated with Multiple Conditions (OR = 9.50, 95% CI = 5.82 to 15.50), CVD (OR = 3.82, 95% CI = 2.96 to 4.93), and Thyroid (OR = 2.86, 95% CI = 2.12 to 3.85) groups. Conclusions: While most AYA HL survivors were in the Low Morbidity group, those with public insurance or intense treatment may be at higher risk for multiple conditions.
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (6)
Open AccessIdentifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma
Background: We examined late effects clustering among adolescent and young adult (AYA; age 15-39 years at diagnosis) Hodgkin lymphoma (HL) survivors and identified characteristics associated with each cluster. Methods: We included AYAs with HL in 2006-2018 from the California and Utah Cancer Registries linked to statewide hospitalization, emergency department, and ambulatory surgery visit data. We identified severe late effects >2 years after cancer diagnosis in 9 late effects categories. Latent class analysis (LCA) was used to identify late effects clusters. Multinomial logistic regression models estimated adjusted associations of demographic and treatment characteristics with LCA late effect group. Results: We identified 4635 AYA HL survivors with median follow-up of 8.2 years and 4 late effects groups: 77.1% had a low probability of any late effect (Low Morbidity), 12.8% had high probability of Thyroid disorders, 8.0% had high probability of Cardiovascular Disease (CVD), and 2.1% had high probability of Multiple Conditions (CVD, diabetes/pancreatic, thyroid, and renal diseases). Publicly insured AYAs were more likely than those with private insurance to be in the CVD (OR = 1.53, 95% CI = 1.18 to 1.98) and Multiple Conditions (OR = 2.17, 95% CI = 1.29 to 3.66) than the Low Morbidity group. AYAs with radiation were more likely to be in the Multiple Conditions (OR = 2.31, 95% CI = 1.41 to 3.78) and Thyroid (OR = 2.81, 95% CI = 2.20 to 3.58) groups. Hematopoietic cell transplantation was associated with Multiple Conditions (OR = 9.50, 95% CI = 5.82 to 15.50), CVD (OR = 3.82, 95% CI = 2.96 to 4.93), and Thyroid (OR = 2.86, 95% CI = 2.12 to 3.85) groups. Conclusions: While most AYA HL survivors were in the Low Morbidity group, those with public insurance or intense treatment may be at higher risk for multiple conditions.
- 1 September 2025
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 11 (9) , 1091-1093
COVID-19 Pandemic and Posttreatment Breast Cancer Surveillance and Outcomes
This Research Letter compares use of surveillance imaging in pre–COVID-19 and post–COVID-19 periods for patients with an early-stage breast cancer diagnosis within a large integrated health care system.
- 1 September 2025
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 11 (9) , 1091-1093
COVID-19 Pandemic and Posttreatment Breast Cancer Surveillance and Outcomes
This Research Letter compares use of surveillance imaging in pre–COVID-19 and post–COVID-19 periods for patients with an early-stage breast cancer diagnosis within a large integrated health care system.
- Open Access
- 15 July 2025
- Published by Frontiers Media SA in Frontiers in Health Services
- Vol. 5, 1595934
Locally-tailored vs. centrally-administered strategies for implementation of primary human papillomavirus (HPV) screening in an integrated healthcare system: a qualitative research study
Introduction: Primary human papillomavirus(HPV) testing is recommended for cervical cancer screening for women aged 30–65 years without a history of abnormal results. However, there is little clear guidance regarding effective strategies for implementing primary HPV screening. As part of an ongoing randomized trial comparing implementation strategies for primary HPV testing (a centrally administered + usual care strategy vs. centrally administered + locally tailored strategy), we evaluated clinician experiences and perceptions of large-scale implementation of primary HPV screening in an integrated healthcare system, Kaiser Permanente Southern California.Materials and methods: We conducted qualitative interviews with internal medicine, family medicine and obstetrics/gynecology clinicians to gain insight into fidelity to the interventions and implementation strategies, barriers and facilitators to implementation, and recommendations. Participants from both arms of the trial were recruited. Interview guides were developed with the Consolidated Framework for Implementation Research (CFIR). We recruited physicians, licensed vocational nurses, and medical assistants after primary HPV screening had been implemented. Interviews were recorded and transcribed. Using a team coding approach, we developed an initial coding structure refined during iterative analysis; data were subsequently organized thematically into domains, key themes, and sub-themes using thematic analysis, followed by framework analysis informed by CFIR.Results: Thirty-two interviews were conducted. Participants in both arms of the trial noted high awareness, preparedness, buy-in, and fidelity to the new screening process. Initial barriers concerned specimen collection, proper ordering, and lab delays. An unanticipated barrier was the length of time needed to return lab results for reflexive cytology tests after a positive HPV result which reportedly increased patient anxiety. Participants in both arms reported fidelity to the centralized strategy (e.g., attending webinars, leadership announcements). In the local-tailored arm, few participants recalled the local-tailored resources.Discussion: The centralized strategy was perceived as highly acceptable and feasible, and fidelity to the associated interventions appear to be facilitators of practice change. Recommendations for improving implementation included patient education, outreach and ongoing clinician training. Findings can be applied to other health systems and settings considering primary HPV screening implementation, particularly those within the U.S. or with a similar health care model. Trial Registration: ClinicalTrials.gov, identifier #NCT04371887
- 15 July 2025
- Published by Frontiers Media SA in Frontiers in Health Services
- Vol. 5, 1595934
Open AccessLocally-tailored vs. centrally-administered strategies for implementation of primary human papillomavirus (HPV) screening in an integrated healthcare system: a qualitative research study
Introduction: Primary human papillomavirus(HPV) testing is recommended for cervical cancer screening for women aged 30–65 years without a history of abnormal results. However, there is little clear guidance regarding effective strategies for implementing primary HPV screening. As part of an ongoing randomized trial comparing implementation strategies for primary HPV testing (a centrally administered + usual care strategy vs. centrally administered + locally tailored strategy), we evaluated clinician experiences and perceptions of large-scale implementation of primary HPV screening in an integrated healthcare system, Kaiser Permanente Southern California.Materials and methods: We conducted qualitative interviews with internal medicine, family medicine and obstetrics/gynecology clinicians to gain insight into fidelity to the interventions and implementation strategies, barriers and facilitators to implementation, and recommendations. Participants from both arms of the trial were recruited. Interview guides were developed with the Consolidated Framework for Implementation Research (CFIR). We recruited physicians, licensed vocational nurses, and medical assistants after primary HPV screening had been implemented. Interviews were recorded and transcribed. Using a team coding approach, we developed an initial coding structure refined during iterative analysis; data were subsequently organized thematically into domains, key themes, and sub-themes using thematic analysis, followed by framework analysis informed by CFIR.Results: Thirty-two interviews were conducted. Participants in both arms of the trial noted high awareness, preparedness, buy-in, and fidelity to the new screening process. Initial barriers concerned specimen collection, proper ordering, and lab delays. An unanticipated barrier was the length of time needed to return lab results for reflexive cytology tests after a positive HPV result which reportedly increased patient anxiety. Participants in both arms reported fidelity to the centralized strategy (e.g., attending webinars, leadership announcements). In the local-tailored arm, few participants recalled the local-tailored resources.Discussion: The centralized strategy was perceived as highly acceptable and feasible, and fidelity to the associated interventions appear to be facilitators of practice change. Recommendations for improving implementation included patient education, outreach and ongoing clinician training. Findings can be applied to other health systems and settings considering primary HPV screening implementation, particularly those within the U.S. or with a similar health care model. Trial Registration: ClinicalTrials.gov, identifier #NCT04371887
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500003
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
PURPOSE: There is little guidance for decision making in chronic myeloid leukemia (CML) after patients achieve molecular remission. Our study addresses this gap by developing a risk prediction model for molecular relapse using early longitudinal factors, such as BCR::ABL1 biomarker-level changes and treatment adherence. METHODS: We analyzed electronic health record data of patients with CML diagnosed between 2007 and 2019 from an integrated health system. We used a time-to-event modeling framework using a Cox proportional hazards approach where we evaluated time from molecular remission to molecular relapse. The main predictors were early changes in BCR::ABL1 levels from treatment initiation to the first follow-up measurement (typically around 3 months) and treatment adherence in the first 6 months, categorized as perfect (≥0.98) or less-than-perfect (<0.98). Model performance was assessed through five-fold cross-validation combined with 100 Monte Carlo bootstrapping iterations to ensure robustness and minimize bias. RESULTS: Patients with early improvement in BCR::ABL1 levels had a 70% lower risk relapse (hazard ratio [HR], 0.30 [95% CI, 0.15 to 0.59]) compared with those without early molecular response. Perfect adherence during this critical early phase of treatment was associated with a 56% lower relapse risk (HR, 0.44 [95% CI, 0.22 to 0.85]). Predictive accuracy was high at 6 months (AUC, 0.90; 95% CI, 0.87 to 0.95) and 1-year postremission (AUC, 0.78; 95% CI, 0.74 to 0.81). Relapse risk was significantly higher among Black, Asian, and Hispanic patients compared with non-Hispanic White patients. CONCLUSION: Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500003
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
PURPOSE: There is little guidance for decision making in chronic myeloid leukemia (CML) after patients achieve molecular remission. Our study addresses this gap by developing a risk prediction model for molecular relapse using early longitudinal factors, such as BCR::ABL1 biomarker-level changes and treatment adherence. METHODS: We analyzed electronic health record data of patients with CML diagnosed between 2007 and 2019 from an integrated health system. We used a time-to-event modeling framework using a Cox proportional hazards approach where we evaluated time from molecular remission to molecular relapse. The main predictors were early changes in BCR::ABL1 levels from treatment initiation to the first follow-up measurement (typically around 3 months) and treatment adherence in the first 6 months, categorized as perfect (≥0.98) or less-than-perfect (<0.98). Model performance was assessed through five-fold cross-validation combined with 100 Monte Carlo bootstrapping iterations to ensure robustness and minimize bias. RESULTS: Patients with early improvement in BCR::ABL1 levels had a 70% lower risk relapse (hazard ratio [HR], 0.30 [95% CI, 0.15 to 0.59]) compared with those without early molecular response. Perfect adherence during this critical early phase of treatment was associated with a 56% lower relapse risk (HR, 0.44 [95% CI, 0.22 to 0.85]). Predictive accuracy was high at 6 months (AUC, 0.90; 95% CI, 0.87 to 0.95) and 1-year postremission (AUC, 0.78; 95% CI, 0.74 to 0.81). Relapse risk was significantly higher among Black, Asian, and Hispanic patients compared with non-Hispanic White patients. CONCLUSION: Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.